BR9913932A - Uso de análogos de glp-1 no tratamento de derrame - Google Patents

Uso de análogos de glp-1 no tratamento de derrame

Info

Publication number
BR9913932A
BR9913932A BR9913932-4A BR9913932A BR9913932A BR 9913932 A BR9913932 A BR 9913932A BR 9913932 A BR9913932 A BR 9913932A BR 9913932 A BR9913932 A BR 9913932A
Authority
BR
Brazil
Prior art keywords
glp
stroke
analogs
treatment
administered
Prior art date
Application number
BR9913932-4A
Other languages
English (en)
Portuguese (pt)
Inventor
Suad Efendic
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR9913932A publication Critical patent/BR9913932A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/26Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Mechanical Light Control Or Optical Switches (AREA)
  • Complex Calculations (AREA)
BR9913932-4A 1998-09-24 1999-09-22 Uso de análogos de glp-1 no tratamento de derrame BR9913932A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10171998P 1998-09-24 1998-09-24
PCT/US1999/022026 WO2000016797A2 (en) 1998-09-24 1999-09-22 Use of glp-1 or analogs in treatment of stroke

Publications (1)

Publication Number Publication Date
BR9913932A true BR9913932A (pt) 2001-10-16

Family

ID=22286048

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9913932-4A BR9913932A (pt) 1998-09-24 1999-09-22 Uso de análogos de glp-1 no tratamento de derrame

Country Status (12)

Country Link
EP (1) EP1115421B1 (https=)
JP (1) JP2002526454A (https=)
CN (1) CN1163267C (https=)
AT (1) ATE433324T1 (https=)
AU (1) AU766375B2 (https=)
BR (1) BR9913932A (https=)
CA (1) CA2344056A1 (https=)
DE (1) DE69940975D1 (https=)
ES (1) ES2325777T3 (https=)
MY (1) MY155270A (https=)
TW (1) TWI260986B (https=)
WO (1) WO2000016797A2 (https=)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6284725B1 (en) 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
US6429197B1 (en) 1998-10-08 2002-08-06 Bionebraska, Inc. Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain
US7259136B2 (en) 1999-04-30 2007-08-21 Amylin Pharmaceuticals, Inc. Compositions and methods for treating peripheral vascular disease
EP2213743A1 (en) 2000-04-12 2010-08-04 Human Genome Sciences, Inc. Albumin fusion proteins
JP2003532691A (ja) * 2000-05-05 2003-11-05 ノボ ノルディスク アクティーゼルスカブ 重症疾患神経障害
CN103356996A (zh) 2000-05-19 2013-10-23 埃米林药品公司 Glp-1用于制备治疗急性冠脉综合征的药物的用途
ATE408414T1 (de) 2001-07-31 2008-10-15 Us Gov Health & Human Serv Glp 1 exendin 4 peptidanaloga und deren verwendungen
CN1561224A (zh) * 2001-10-01 2005-01-05 伊莱利利公司 降低与严重疾病相关的死亡率和发病率的方法
AU2002364586A1 (en) 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
US20030199445A1 (en) 2002-02-07 2003-10-23 Knudsen Lotte Bjerre Use of GLP-1 compound for treatment of critically ill patients
PL209734B1 (pl) 2002-02-20 2011-10-31 Emisphere Tech Inc Preparat farmaceutyczny zawierający związek GLP-1 i czynnik dostarczający oraz jego zastosowanie
DK1641823T3 (da) 2003-06-12 2011-12-12 Lilly Co Eli GLP-1-analog fusionsproteiner
ATE461217T1 (de) 2003-12-18 2010-04-15 Novo Nordisk As Glp-1-verbindungen
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
HUE027902T2 (en) 2004-02-09 2016-11-28 Human Genome Sciences Inc Corp Service Company Albumin fusion proteins
CA2608311C (en) 2005-05-13 2012-11-27 Eli Lilly And Company Glp-1 pegylated compounds
CN101258163B (zh) 2005-06-30 2013-08-21 益普生制药股份有限公司 Glp-1药物组合物
US8765669B2 (en) 2008-06-17 2014-07-01 Glytech, Inc. Glycosylated GLP-1 peptide
EP2216042A1 (en) 2009-02-09 2010-08-11 Ipsen Pharma S.A.S. GLP-1 analogues pharmaceutical compositions
US8614185B2 (en) 2009-05-04 2013-12-24 Centocor Ortho Biotech Inc. Fusion proteins of alpha-MSH derivatives and Fc
WO2010129248A1 (en) 2009-05-06 2010-11-11 Centocor Ortho Biotech Inc. Melanocortin receptor binding conjugates
KR20120101037A (ko) 2009-10-30 2012-09-12 오츠카 가가쿠 가부시키가이샤 항원성 glp?1 아날로그의 당쇄 부가체
JP6006118B2 (ja) 2009-12-16 2016-10-12 ノヴォ ノルディスク アー/エス Glp−1アナログ及び誘導体
JP2013530993A (ja) 2010-07-02 2013-08-01 アンジオケム インコーポレーテッド 治療用コンジュゲートのための短く且つd−アミノ酸を含有するポリペプチドおよびその使用
JP6039569B2 (ja) * 2010-11-09 2016-12-07 ノヴォ ノルディスク アー/エス 二重アシル化されたglp−1誘導体
SI2651398T1 (en) 2010-12-16 2018-04-30 Novo Nordisk A/S SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND SOL N- (8- (2-HYDROXYBENZOIL) AMINO) CAPRICULATE ACIDS
PL2696687T3 (pl) 2011-04-12 2017-06-30 Novo Nordisk A/S Pochodne podwójnie acylowanej GLP-1
PT2827845T (pt) 2012-03-22 2019-03-29 Novo Nordisk As Composições compreendendo um agente de entrega e sua preparação
HRP20181447T1 (hr) 2012-03-22 2018-11-02 Novo Nordisk A/S Pripravci glp-1 peptida i njihova priprava
JP6517690B2 (ja) 2012-06-20 2019-05-22 ノヴォ ノルディスク アー/エス ペプチド及び送達剤を含む錠剤製剤
KR102272671B1 (ko) 2013-05-02 2021-07-06 노보 노르디스크 에이/에스 Glp-1 화합물의 경구 투여
US20160122406A1 (en) * 2013-06-07 2016-05-05 The Administrators Of The Tulane Educational Fund Analogs of pituitary adenylate cyclase-activating polypeptide (pacap) and methods for their use
CN104371019B (zh) 2013-08-13 2019-09-10 鸿运华宁(杭州)生物医药有限公司 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
KR101825048B1 (ko) 2014-12-31 2018-02-05 주식회사 제넥신 GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도
PT3257524T (pt) 2015-02-11 2020-11-27 Gmax Biopharm Llc Preparação de solução estabilizada de proteína de fusão de anticorpo glp-1r farmacêutica
CN105254720B (zh) * 2015-11-18 2018-10-09 暨南大学 一种多受体激动剂po13及应用
WO2018113340A1 (zh) * 2016-12-20 2018-06-28 中国药科大学 多肽p11及其用途
JP6898518B2 (ja) 2018-02-02 2021-07-07 ノヴォ ノルディスク アー/エス Glp−1アゴニスト、n−(8−(2−ヒドロキシベンゾイル)アミノ)カプリル酸の塩及び滑沢剤を含む固形組成物
CN117126279A (zh) 2018-03-20 2023-11-28 鸿运华宁(杭州)生物医药有限公司 Gipr抗体及其与glp-1的融合蛋白质,以及其药物组合物和应用
CN112521501A (zh) 2019-09-18 2021-03-19 鸿运华宁(杭州)生物医药有限公司 Gipr抗体及其与glp-1的融合蛋白质,以及其药物组合物和应用
CN115397455A (zh) * 2020-01-16 2022-11-25 上海仁会生物制药股份有限公司 Glp-1给药方案
US20240050531A1 (en) * 2020-12-16 2024-02-15 The Chinese University Of Hong Kong A method for reversing aging brain functional decline
CN116970062B (zh) * 2022-04-29 2024-04-09 南京知和医药科技有限公司 一种超长效glp-1多肽衍生物及其制备方法和用途
CN119909159A (zh) * 2022-06-23 2025-05-02 广州银诺医药集团股份有限公司 一种改进的glp-1受体激动剂的融合蛋白在治疗疾病中的用途
CN119744271A (zh) 2022-09-08 2025-04-01 鸿运华宁(杭州)生物医药有限公司 Gipr抗体及其与fgf21的融合蛋白,以及其药物组合物和应用
CN119569847A (zh) * 2024-12-03 2025-03-07 中国科学院上海有机化学研究所 Glp-1变体及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK36392D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
US6277819B1 (en) * 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
IL128332A0 (en) * 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
US6006753A (en) * 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
EP1049486A4 (en) * 1997-12-05 2006-01-04 Lilly Co Eli GLP-1 FORMULATIONS

Also Published As

Publication number Publication date
MY155270A (en) 2015-09-30
AU6398599A (en) 2000-04-10
EP1115421A2 (en) 2001-07-18
JP2002526454A (ja) 2002-08-20
AU766375B2 (en) 2003-10-16
ES2325777T3 (es) 2009-09-16
WO2000016797A2 (en) 2000-03-30
CN1163267C (zh) 2004-08-25
ATE433324T1 (de) 2009-06-15
DE69940975D1 (de) 2009-07-23
WO2000016797A3 (en) 2000-05-25
CA2344056A1 (en) 2000-03-30
TWI260986B (en) 2006-09-01
CN1322137A (zh) 2001-11-14
EP1115421B1 (en) 2009-06-10

Similar Documents

Publication Publication Date Title
BR9913932A (pt) Uso de análogos de glp-1 no tratamento de derrame
BR9711447A (pt) Uso de glp-1 an logos no tratamento de enfarte de mioc rdio
EA200000747A1 (ru) СПОСОБ ВВЕДЕНИЯ AspB28-ИНСУЛИНА ЧЕЛОВЕКА
CY1121113T1 (el) Θεραπεια της νοσου ρομρε
NZ334270A (en) Glucagon like peptide (GLP-1), analogs and derivatives to treat post surgical catabolic changes and insulin resistance
DK0850068T3 (da) Lipidekstrakt med antiinflammatorisk aktivitet
KR950002785A (ko) 골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜
PT998287E (pt) Utilizacao de levobupivacaina
DK261490D0 (da) New pharmaceutical compound
ES2157107T3 (es) Uso de moxonidina para el tratamiento del dolor neuropatico.
ES2068714T3 (es) Derivados de pirimidina para aumentar la actividad antitumoral.
GR3032224T3 (en) Therapeutic agent for threatened abortion.
ES2189206T3 (es) Beta-alcoxiacrilatos contra la malaria.
ES2191206T3 (es) Nueva utilizacion de la creatina.
BR9710206A (pt) Uso de um agente de interleucina-8 e formulação farmacéutica antiviral
DE60120159D1 (de) Hautpflegemittel
FR2818147B1 (fr) Nouvelle application therapeutique d'un derive de la thienyclyclohexylamine
TR200000728T2 (tr) Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı.
EP1566180A3 (en) Use of GLP-1 or Analogs in Treatment of Myocardial Infarction
EA200300222A1 (ru) Лечение гепатита c с помощью тимозина, интерферона и рибавирина
MX9705920A (es) Tratamiento de neuropatia diabetica.
ES2101000T3 (es) Uso de bmy 14802 en el tratamiento de la ansiedad en pacientes con sindrome de abstinencia de benzodiazepinas.
AR006382A1 (es) Procedimiento para el tratamiento del envejecimiento cutaneo y de lesiones atroficas mediante la administracion de una preparacion conteniendoacido hialuronico y/o hialuronatos.
AR016920A1 (es) FORMULACIoN DE 8A-AZALIDAS uTIL PARA EL TRATAMIENTO O PREVENCIoN DE UNA INFECCION ENTÉRICA O RESPIRATORIA BACTERIANA
UA19504A (uk) Засіб для лікуваhhя гhійhих запалеhь шкіри та підшкірhої клітковиhи

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 10 (VIII) DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.